3 news items
Groundbreaking Study by MAIA Biotechnology (NYSE: MAIA) Indicates Promising New Treatment for Advanced Lung Cancer
CORT
HALO
MAIA
6 Jun 24
.
The THIO-101 Phase 2 trial represents a pioneering effort to assess the efficacy of THIO when used in conjunction
Corcept Therapeutics Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)
CORT
29 May 24
(NASDAQ:CORT), offering a diverse set of opinions from bullish to bearish.
Summarizing their recent assessments, the table below
The Analyst Verdict: Corcept Therapeutics In The Eyes Of 4 Experts
CORT
2 May 24
, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance
- Prev
- 1
- Next